The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer.

To investigate the efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer (SCLC). 64 patients diagnosed with SCLC in our hospital from April 2013 to June 2015 were retrospectively analyzed. Thirty-two patients in group A were treated with irinotecan combined with nedaplatin, while 32 patients in group B were treated with irinotecan combined with cisplatin. The treatment efficacy was evaluated after 3 cycles of chemotherapy. Abbott ARCHIITECT i2000SR chemiluminescence microparticle immunoassay analyzer was used to detect serum CEA, CA19.9 and CA125. The levels of serum CEA, CA19.9 and CA125 were assessed before and after treatment. In the two groups, the levels of serum CEA, CA19.9 and CA125 of the patients after treatment were lower than those before treatment (p<0.05). The main toxic side effect of the patients was gastrointestinal reaction in both groups. The total incidence of toxic side effects in group A was lower than that in group B (p<0.05). The efficacy of irinotecan combined with nedaplatin is good and the safety is high in the treatment of SCLC and it can be used as a clinical treatment method of SCLC and is worthy of being generalized.